Acquisition synergies Post-acquisition by Vaxart, explore sales opportunities through integrated oral vaccine platforms, leveraging Aviragen’s phase stage antivirals and Vaxart’s vaccine development capabilities to offer combination product candidates and expanded portfolio to pharma partners.

Oral vaccine expansion Target interest from pharma and biotech partners in oral vaccines for influenza, norovirus, and RSV, highlighting joint development or licensing opportunities that align with the merged entity's strategic direction.

Gene-based vaccines Capitalize on preclinical gene-based vaccine platform data demonstrating high antibody responses to approach potential collaborators or funders for platform licensing, co-development, or contract research services.

Capid and fusion inhibitors Market the three Phase 2 assets (vapendavir, enzaplatovir, BTA074) to infectious disease focused CDMOs and biotechs seeking antivirals with novel mechanisms, emphasizing collaboration for further clinical development or out-licensing.

Small-to-midcap partner-fit Position as a nimble, biotechnology-focused partner with a global disease impact portfolio to mid- and large-cap pharma seeking external innovation, offering collaboration, co-development, or strategic investments aligned with an integrated vaccine and antiviral platform.